AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37369412 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 189
Study 37369415 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine childhood vaccinations
Number of subjects: 0
Study 37369415 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanus and MMR vaccinations
Number of subjects: 0
Study 37369415 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR2 and Tetanus boosters
Number of subjects: 0
Study 37369415 — intervention group
Group type: EXPERIMENTAL
Intervention: Preschool boosters (tetanus and MMR2)
Number of subjects: 0
Study 37369421 — intervention group
Group type: EXPERIMENTAL
Intervention: high-velocity and articulation techniques
Number of subjects: 30
Study 37369421 — intervention group
Group type: EXPERIMENTAL
Intervention: soft-tissue massage
Number of subjects: 30
Study 37369421 — intervention group
Group type: EXPERIMENTAL
Intervention: craniosacral techniques
Number of subjects: 30
Study 37369421 — intervention group
Group type: EXPERIMENTAL
Intervention: combination of high-velocity, soft-tissue massage, and craniosacral techniques
Number of subjects: 30
Study 37369422 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days antibiotic therapy
Number of subjects: 3626
Study 37369422 — intervention group
Group type: COMPARATOR
Intervention: 14 days antibiotic therapy
Number of subjects: 3626
Study 37369426 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management (non-surgical group)
Number of subjects: 604
Study 37369426 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical management (surgical group)
Number of subjects: 604
Study 37369531 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemia on day 1
Number of subjects: 21
Study 37369531 — intervention group
Group type: EXPERIMENTAL
Intervention: Antecedent hypoglycemia
Number of subjects: 21
Study 37369550 — intervention group
Group type: EXPERIMENTAL
Intervention: v-TAC (venous to arterial conversion method)
Number of subjects: 0
Study 37369550 — intervention group
Group type: COMPARATOR
Intervention: ABG (arterial blood gas sampling)
Number of subjects: 0
Study 37369550 — intervention group
Group type: COMPARATOR
Intervention: Capillary blood gas (CBG) sampling
Number of subjects: 0
Study 37369550 — intervention group
Group type: COMPARATOR
Intervention: Venous blood gas (VBG) sampling
Number of subjects: 0
Study 37369551 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnoea (OSA) defined as AHI ≥15 events/hour in patients with hypertension.
Number of subjects: 1927
Study 37369551 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnoea (OSA) in patients without hypertension.
Number of subjects: 1927
Study 37369551 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnoea (OSA) in patients with grade 3 hypertension.
Number of subjects: 1927
Study 37369551 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnoea (OSA) in patients with grade 1 or 2 hypertension.
Number of subjects: 1927
Study 37369602 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal CD8
Number of subjects: 0
Study 37369602 — intervention group
Group type: COMPARATOR
Intervention: Flow cytometry assessments of blood and CSF CD20
Number of subjects: 0
Study 37369815 — intervention group
Group type: EXPERIMENTAL
Intervention: IO-tyrosine kinase inhibitor (IO + TKI) combinations
Number of subjects: 729
Study 37369815 — intervention group
Group type: COMPARATOR
Intervention: Dual immuno-oncology (IO + IO) therapy
Number of subjects: 729
Study 37369826 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (25 mg/day)
Number of subjects: 301
Study 37369826 — intervention group
Group type: COMPARATOR
Intervention: Basal long-acting insulin
Number of subjects: 301
Study 37369832 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonates with ASD
Number of subjects: 716
Study 37369832 — intervention group
Group type: COMPARATOR
Intervention: Neonates without ASD (control)
Number of subjects: 716
Study 37369852 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropidoxuridine-capecitabine-radiotherapy
Number of subjects: 1
Study 37369887 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients informed of having a hernia on imaging results (occult hernias)
Number of subjects: 169
Study 37369887 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients informed of having a hernia on imaging results (clinical hernias)
Number of subjects: 169
Study 37369887 — intervention group
Group type: COMPARATOR
Intervention: Patients completing the follow-up survey before being informed of the hernia (occult hernias)
Number of subjects: 169
Study 37369887 — intervention group
Group type: COMPARATOR
Intervention: Patients completing the follow-up survey before being informed of the hernia (clinical hernias)
Number of subjects: 169
Study 37369917 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET/CT
Number of subjects: 79
Study 37369917 — intervention group
Group type: EXPERIMENTAL
Intervention: Indexed volume of the proximal half of the thoracic aorta
Number of subjects: 79
Study 37369955 — intervention group
Group type: EXPERIMENTAL
Intervention: Difelikefalin (single intravenous doses)
Number of subjects: 12
Study 37369994 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital innovation for clinical decision making in polypharmacy
Number of subjects: 218
Study 37370032 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with mFOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin, and irinotecan), up to 5 cycles.
Number of subjects: 50
Study 37370032 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with mFOLFOXIRI
Number of subjects: 50
Study 37370055 — intervention group
Group type: EXPERIMENTAL
Intervention: Ntombi Vimbela! (NV!) intervention, comprising ten workshop sessions of 3.5 hours each, focusing on sexuality empowerment, gender and social norm change, early-risk identification, self-defence, resistance, and mental wellbeing.
Number of subjects: 98
Study 37370064 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-treated healing abutment
Number of subjects: 30
Study 37370064 — intervention group
Group type: COMPARATOR
Intervention: Machined healing abutment (Control)
Number of subjects: 30
Study 37370125 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading intervention using Accessible Literacy Learning (ALL) strategies, delivered in a one-to-one format over 18 months starting March 2023.
Number of subjects: 40
Study 37370135 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 340
Study 37370135 — intervention group
Group type: COMPARATOR
Intervention: Usual-care
Number of subjects: 340
Study 37370150 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-based protocol
Number of subjects: 40
Study 37370150 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluid therapy
Number of subjects: 40
Study 37370174 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC) TB treatment + placebo
Number of subjects: 354
Study 37370174 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of Care (SoC) TB treatment + acetylsalicylic acid (ASA)
Number of subjects: 354
Study 37370174 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of Care (SoC) TB treatment + ibuprofen (Ibu)
Number of subjects: 354
Study 37370204 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated allogeneic hematopoietic stem cell transplant with tolerogenic CD8 + /T-cell receptor - facilitating cells (FCR001) and low-dose, nonmyeloablative conditioning.
Number of subjects: 37
Study 37370204 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated allogeneic hematopoietic stem cell transplant (tolerant participants).
Number of subjects: 37
Study 37370204 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care patients on immunosuppression (IS).
Number of subjects: 37
Study 37370238 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine collaborative care for PTSD
Number of subjects: 1071
Study 37370238 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1071
Study 37370238 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making tools
Number of subjects: 1071
Study 37370995 — intervention group
Group type: EXPERIMENTAL
Intervention: MammoWave microwave imaging device
Number of subjects: 600
Study 37372153 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV9.SMN (Zolgensma) for SMA
Number of subjects: 0
Study 37372153 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV9.IGHMBP2 for IGHMBP2 disorders
Number of subjects: 0
Study 37372414 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexanolone (allopregnanolone)
Number of subjects: 0
Study 37373625 — intervention group
Group type: EXPERIMENTAL
Intervention: E4 15 mg once daily for 21 days
Number of subjects: 0
Study 37373625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37373853 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with long COVID symptoms (n = 44)
Number of subjects: 146
Study 37373853 — intervention group
Group type: COMPARATOR
Intervention: Patients without long COVID symptoms (n = 102)
Number of subjects: 146
Study 37373857 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic compression combined with standard venous thromboembolism (VTE) therapy
Number of subjects: 47
Study 37373857 — intervention group
Group type: COMPARATOR
Intervention: Standard venous thromboembolism (VTE) therapy (control group)
Number of subjects: 47
Study 37374884 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0
Study 37375656 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of oligomalt (180 g/day)
Number of subjects: 24
Study 37375656 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose of oligomalt (80 g/day) + maltodextrin (100 g/day)
Number of subjects: 24
Study 37375656 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (180 g/day)
Number of subjects: 24
Study 37376480 — intervention group
Group type: EXPERIMENTAL
Intervention: PXVX0047 (Ad4 and Ad7 components administered orally in a single dose to 11 subjects)
Number of subjects: 14
Study 37376480 — intervention group
Group type: COMPARATOR
Intervention: Control Ad4/Ad7 vaccine (currently in use by the US military, administered to 3 subjects)
Number of subjects: 14
Study 37376480 — intervention group
Group type: EXPERIMENTAL
Intervention: PXVX0047 (Ad4 component)
Number of subjects: 14
Study 37376649 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir/Lamivudine (DTG/3TC)
Number of subjects: 734
Study 37376649 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir alafenamide-based regimens (TBR)
Number of subjects: 734
Study 37376649 — intervention group
Group type: EXPERIMENTAL
Intervention: Archived major RAMs presence
Number of subjects: 734
Study 37376804 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 time per week of recreational team handball
Number of subjects: 54
Study 37376804 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 times per week of recreational team handball
Number of subjects: 54
Study 37376804 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 times per week of recreational team handball
Number of subjects: 54
Study 37376804 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 54
Study 37376817 — intervention group
Group type: EXPERIMENTAL
Intervention: Subannular repair
Number of subjects: 94
Study 37376989 — intervention group
Group type: EXPERIMENTAL
Intervention: Target LDL cholesterol <70 mg/dL with >50% LDL cholesterol reduction from baseline
Number of subjects: 2860
Study 37376989 — intervention group
Group type: EXPERIMENTAL
Intervention: Target LDL cholesterol <70 mg/dL with <50% LDL cholesterol reduction from baseline
Number of subjects: 2860
Study 37376989 — intervention group
Group type: COMPARATOR
Intervention: Target LDL cholesterol 100±10 mg/dL
Number of subjects: 2860
Study 37377385 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg daily
Number of subjects: 100
Study 37377385 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate 25 mg subcutaneously weekly
Number of subjects: 100
Study 37377462 — intervention group
Group type: EXPERIMENTAL
Intervention: Concise Health Risk Tracking Scale - Self Report (CHRT-SR)
Number of subjects: 403
Study 37377468 — intervention group
Group type: EXPERIMENTAL
Intervention: Telecare-based intervention program (3-month program with online nurse case management, online resource center, discussion forum)
Number of subjects: 0
Study 37377468 — intervention group
Group type: COMPARATOR
Intervention: Usual services provided by community centers
Number of subjects: 0
Study 37377605 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous iNKT cells combined with PD-1
Number of subjects: 15
Study 37377613 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg i.v. every 3 weeks and cabozantinib 60 mg orally once daily
Number of subjects: 45
Study 37377890 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous RNA-electroporated cMET-directed CAR T cells (1 × 10e8 T cells/dose, up to six infusions)
Number of subjects: 7
Study 37377890 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous RNA-electroporated cMET-directed CAR T cells
Number of subjects: 7
Study 37378404 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan treatment
Number of subjects: 83
Study 37378490 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0
Study 37378706 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcified plaque with lipidic materials
Number of subjects: 0
Study 37378706 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy and intravascular ultrasound imaging
Number of subjects: 0
Study 37378754 — intervention group
Group type: EXPERIMENTAL
Intervention: eptinezumab 100 mg, 300 mg
Number of subjects: 1072
Study 37378754 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1072
Study 37378806 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Immunoglobulin (IVIg) at 2.0 g/kg induction dose followed by maintenance doses of 0.5, 1.0 or 2.0 g/kg every 3 weeks for 24 weeks
Number of subjects: 142
Study 37378860 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-90001 (100, 200, or 400 mg) administered once daily for 12 weeks
Number of subjects: 16
Study 37378896 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant chemoradiotherapy or RT after induction chemotherapy (IC)
Number of subjects: 34
Study 37378896 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy (IC) alone
Number of subjects: 34
Study 37378966 — intervention group
Group type: EXPERIMENTAL
Intervention: CPVI plus low-voltage-area ablation
Number of subjects: 438
Study 37378966 — intervention group
Group type: COMPARATOR
Intervention: CPVI alone
Number of subjects: 438
Study 37378972 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy (varenicline, dual-form nicotine replacement, or their combination) and behavioral smoking cessation intervention with weight management and physical activity support
Number of subjects: 192
Study 37378972 — intervention group
Group type: COMPARATOR
Intervention: Control group received quitline referrals
Number of subjects: 192
Study 37378972 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 192
Study 37378974 — intervention group
Group type: EXPERIMENTAL
Intervention: Support and Problem Solving (SPS) for 6 weeks
Number of subjects: 342
Study 37378974 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-Behavioral Case Management (CBCM) for 20 weeks
Number of subjects: 342
Study 37378974 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Case Management (CBCM) with Fluoxetine for 26 weeks
Number of subjects: 342
Study 37378974 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-Behavioral Case Management (CBCM) with Placebo for 26 weeks
Number of subjects: 342
Study 37378974 — intervention group
Group type: COMPARATOR
Intervention: Monitoring after remission
Number of subjects: 342
Study 37378974 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition to psychosis
Number of subjects: 342
Study 37378983 — intervention group
Group type: EXPERIMENTAL
Intervention: 3RP-NF
Number of subjects: 228
Study 37378983 — intervention group
Group type: COMPARATOR
Intervention: HEP-NF
Number of subjects: 228
Study 37379001 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day course of antibiotics
Number of subjects: 776
Study 37379055 — intervention group
Group type: EXPERIMENTAL
Intervention: CRCweb (web-based dyadic intervention)
Number of subjects: 20
Study 37379059 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Care (EC)
Number of subjects: 60
Study 37379059 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 60
Study 37379059 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EC and SC
Number of subjects: 60
Study 37379135 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirikizumab (300 mg)
Number of subjects: 1281
Study 37379135 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirikizumab (200 mg)
Number of subjects: 1281
Study 37379135 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Number of subjects: 1281
Study 37379135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1281
Study 37379158 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus platinum-based chemotherapy (experimental group)
Number of subjects: 86
Study 37379158 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (control group)
Number of subjects: 86
Study 37379271 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (8 cycles starting day +1)
Number of subjects: 20
Study 37379271 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic transplant (propensity score-matched cohort)
Number of subjects: 20
Study 37379430 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 790
Study 37379430 — intervention group
Group type: COMPARATOR
Intervention: Platinum-pemetrexed
Number of subjects: 790
Study 37379430 — intervention group
Group type: COMPARATOR
Intervention: Comparator EGFR-TKI
Number of subjects: 790
Study 37379468 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischial containment sockets
Number of subjects: 10
Study 37379468 — intervention group
Group type: EXPERIMENTAL
Intervention: Subischial sockets
Number of subjects: 10
Study 37379468 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrilateral sockets
Number of subjects: 10
Study 37379468 — intervention group
Group type: COMPARATOR
Intervention: All socket designs
Number of subjects: 10
Study 37379470 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37379478 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 sexual partner
Number of subjects: 876
Study 37379478 — intervention group
Group type: COMPARATOR
Intervention: 0 sexual partners
Number of subjects: 876
Study 37379478 — intervention group
Group type: COMPARATOR
Intervention: 2-5 sexual partners
Number of subjects: 876
Study 37379478 — intervention group
Group type: COMPARATOR
Intervention: >5 sexual partners
Number of subjects: 876
Study 37379495 — intervention group
Group type: EXPERIMENTAL
Intervention: Gilteritinib 120 mg once daily
Number of subjects: 80
Study 37379495 — intervention group
Group type: EXPERIMENTAL
Intervention: Gilteritinib as single-agent maintenance therapy
Number of subjects: 80
Study 37379502 — intervention group
Group type: EXPERIMENTAL
Intervention: Lazertinib 240 mg once daily orally
Number of subjects: 393
Study 37379502 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib 250 mg once daily orally
Number of subjects: 393
Study 37379532 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputnik V vaccine
Number of subjects: 94
Study 37379532 — intervention group
Group type: EXPERIMENTAL
Intervention: AstraZeneca vaccine
Number of subjects: 94
Study 37379532 — intervention group
Group type: COMPARATOR
Intervention: Ocrelizumab treatment
Number of subjects: 94
Study 37379532 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall vaccination (Sputnik V or AstraZeneca)
Number of subjects: 94
Study 37379584 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplantation from HIV-positive donors
Number of subjects: 29
Study 37379584 — intervention group
Group type: COMPARATOR
Intervention: Liver transplantation from HIV-negative donors
Number of subjects: 29
Study 37379764 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab plus binimetinib 45 mg
Number of subjects: 35
Study 37379764 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab plus binimetinib 30 mg
Number of subjects: 35
Study 37379764 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib plus binimetinib 45 mg
Number of subjects: 35
Study 37379764 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib plus binimetinib 30 mg
Number of subjects: 35
Study 37380019 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH behavioral counseling over 12 months
Number of subjects: 320
Study 37380019 — intervention group
Group type: COMPARATOR
Intervention: Education on lung health, asthma, and other general health topics (Control)
Number of subjects: 320
Study 37380091 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbronchial cryobiopsy (TBCB) using a 1.1-mm diameter cryoprobe
Number of subjects: 50
Study 37380156 — intervention group
Group type: COMPARATOR
Intervention: ANDV DNA vaccine (2 mg) in a 3-dose schedule (days 1, 29, 169)
Number of subjects: 48
Study 37380156 — intervention group
Group type: COMPARATOR
Intervention: ANDV DNA vaccine (2 mg) in a 4-dose schedule (days 1, 29, 57, 169)
Number of subjects: 48
Study 37380156 — intervention group
Group type: COMPARATOR
Intervention: ANDV DNA vaccine (4 mg) in a 3-dose schedule (days 1, 29, 169)
Number of subjects: 48
Study 37380156 — intervention group
Group type: COMPARATOR
Intervention: ANDV DNA vaccine (4 mg) in a 4-dose schedule (days 1, 29, 57, 169)
Number of subjects: 48
Study 37380156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 37380207 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceive, Recall, Plan and Perform (PRPP) intervention, 9 sessions of 45-60 min over 3 weeks
Number of subjects: 3
Study 37380207 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline measurements of task mastery and cognitive strategy application)
Number of subjects: 3
Study 37380207 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal Attainment Scale and Barthel Index
Number of subjects: 3
Study 37380211 — intervention group
Group type: EXPERIMENTAL
Intervention: TESLA-G (gamified quizzing platform)
Number of subjects: 50
Study 37380211 — intervention group
Group type: COMPARATOR
Intervention: Non-gamified quizzing platform (active control group)
Number of subjects: 50